Remibrutinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 20, 2026

The clinical evidence base for Remibrutinib comprises 2 peer-reviewed publications across 2 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Chronic Urticaria, and Arthritis. Most recent publication: Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM)., Dermatol Ther (Heidelb), 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM).
Yosipovitch G, Mosnaim G, Ortmann CE, et al. · Dermatol Ther (Heidelb) · 2026
PubMed: PMID 41854973 · NCT06868212 (RECLAIM) · Chronic Urticaria
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T, Kaul M, Szántó A, et al. · Ann Rheum Dis · 2024
PubMed: PMID 37932009 · NCT04035668 (LOUiSSe) · Arthritis

Publications by year

2024–2026: 2 publications.

2024

2026

Publications by indication

Chronic Urticaria (1)

Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM).
Dermatol Ther (Heidelb) · 2026 · PMID 41854973 · NCT06868212

Arthritis (1)

Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Ann Rheum Dis · 2024 · PMID 37932009 · NCT04035668

Publications by journal

Dermatol Ther (Heidelb)1 paper
Ann Rheum Dis1 paper

All Remibrutinib publications (2)

2026 (1 paper)

Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM).
Yosipovitch G, Mosnaim G, Ortmann CE, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
PubMed: PMID 41854973 · NCT06868212 (RECLAIM) · Chronic Urticaria

2024 (1 paper)

Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T, Kaul M, Szántó A, et al. · Ann Rheum Dis · 2024 · Derived
PubMed: PMID 37932009 · NCT04035668 (LOUiSSe) · Arthritis

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Wed, 20 May 2026 23:49:14 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).